Azithromycin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Bioactive by-products |
| Catalog number | BBF-00245 |
| CAS | 83905-01-5 |
| Molecular Weight | 748.98 |
| Molecular Formula | C38H72N2O12 |
| Purity | > 98% |
Ordering Information
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-00245 | 250 mg | $197 | In stock |
Online Inquiry
Add to cartDescription
Azithromycin is produced by the strain of Erythromycin. The antibacterial activity and pharmacokinetic properties are better than erythromycin, and it is widely used in clinic.
Specification
| Related CAS | 117772-70-0 (dihydrate) 121470-24-4 (monohydrate) |
| Synonyms | azithromycin; Zithromax; Sumamed |
| Storage | -20°C |
| IUPAC Name | (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one |
| Canonical SMILES | CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O |
| InChI | InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1 |
| InChI Key | MQTOSJVFKKJCRP-BICOPXKESA-N |
Properties
| Appearance | White Solid |
| Antibiotic Activity Spectrum | fungi |
| Melting Point | 113-115 °C |
| Density | ~1.2 g/cm3 (Predicted) |
| Solubility | Soluble in DMSO (100 mg/ml at 25 °C), ethanol (100 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), DMF (16 mg/ml), and ethanol: PBS(1:1 pH 7.2) (~0.5 mg/ml). |
Reference Reading
1.Azithromycin versus Doxycycline for Chlamydia.
Kreuter A1, Wieland U2. N Engl J Med. 2016 May 5;374(18):1786-1787.
To the Editor: Within the community of providers who treat sexually transmitted infections, there has been concern that azithromycin may be less effective than doxycycline in treating Chlamydia trachomatis infection. Geisler et al. (Dec. 24 issue)1 report on their trial comparing these two drugs, and in an accompanying editorial, Quinn and Gaydos2 discuss the problem of treatment for these genital tract infections. Yet, neither the article nor the editorial mentions the treatment of extragenital infections. Such infections are not rare. Testing men who have sex with men for rectal and oropharyngeal C. trachomatis infection, as compared with testing for urethral . . .
2.Azithromycin versus Doxycycline for Chlamydia.
N Engl J Med. 2016 May 5;374(18):1786-1787.
To the Editor: Within the community of providers who treat sexually transmitted infections, there has been concern that azithromycin may be less effective than doxycycline in treating Chlamydia trachomatis infection. Geisler et al. (Dec. 24 issue)1 report on their trial comparing these two drugs, and in an accompanying editorial, Quinn and Gaydos2 discuss the problem of treatment for these genital tract infections. Yet, neither the article nor the editorial mentions the treatment of extragenital infections. Such infections are not rare. Testing men who have sex with men for rectal and oropharyngeal C. trachomatis infection, as compared with testing for urethral . . .
3.The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.
Vermeersch K1, Gabrovska M2, Deslypere G3, Demedts IK4, Slabbynck H5, Aumann J3, Ninane V2, Verleden GM1, Troosters T6, Bogaerts K7, Brusselle GG8, Janssens W1. Int J Chron Obstruct Pulmon Dis. 2016 Mar 31;11:687-96. doi: 10.2147/COPD.S95501. eCollection 2016.
BACKGROUND: Long-term use of macrolide antibiotics is effective to prevent exacerbations in chronic obstructive pulmonary disease (COPD). As risks and side effects of long-term intervention outweigh the benefits in the general COPD population, the optimal dose, duration of treatment, and target population are yet to be defined. Hospitalization for an acute exacerbation (AE) of COPD may offer a targeted risk group and an obvious risk period for studying macrolide interventions.
Recommended Products
| BBF-03915 | Clavulanate Potassium (1:1 mixture with silicon dioxide) | Inquiry |
| BBF-01851 | Fumagillin | Inquiry |
| BBF-05781 | Emodepside | Inquiry |
| BBF-03211 | AT-265 | Inquiry |
| BBF-02594 | Pyrrolnitrin | Inquiry |
| BBF-03488 | Streptozotocin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
